What factors impact R&D efficiency and overall success for a small- or medium-sized biotech company? The Center for Medicine Research International (CMR) reported in its Pharmaceutical R&D Factbook 2014 an average success rate of 4.9 % from first toxicity dose to market approval. So what is the reason for the high attrition rate? The reasons are …
Uncover the potential safety risks of your drug candidate. Annually, the European pharma industry invests more than € 35 000 million to identify and develop new drugs, about 22% of which is spent on screening assays and toxicity testing. Of the 5000 compounds that enter pre-clinical testing, only five make it to the clinical phase. …
We’ll be attending CIMT May 21-23, 2019. Meet up with our COO Justyna and Head of Research Erika at booth #10. Poster Abstract #56 on Tuesday, May 21 at 15.00-17.00. Presentation on Thursday, May 23 at 12.00: “Immunotoxicity assessment in a loop with circulating human blood”. See you there!
Immuneed and CTC Clinical Trial Consultants will visit the major cities in Sweden for a joint seminar on how to manage risk and build value in early clinical development: “The Preclinical Human Model”. First out was Lund in March, and this seminar attracted many innovative biotech companies seeking to advance their current pipeline. Now we …
In a close partnership, Immuneed and CTC Clinical Trial Consultants offer a total solution for the preclinical and clinical characterisation of your drug. By using a unique approach, we help you manage risk and build value in your early clinical development. Join our seminar and learn more about the preclinical human model.
Atlas of Science published a summary of our Immuno-Service. Functional and safety assessments of biologics prior to first-in-human (FIH) is key to understand the mode-of-action and safety profile. We have made use of an ex-vivo whole blood assay for its potential in assessment of antibody-based drug candidates.
Read more: http://atlasofscience.org/profiling-biologics-in-circulating-human-whole-blood/
Immuneed AB, a Swedish biotech company, announced today that the company premises are moving from Dag Hammarskjölds väg 13 to Uppsala Science Park at Dag Hammarskjölds väg 10. Strategic relocation is an important step for the company’s continued growth and development in the field of immuno-service. Immuneed’s new facilities are located in the heart of Uppsala’s rapidly developing pharma and biotech community.
Join us at EuropeanAntibody Congress that takes place in Congress Centre, Basel, Switzerland,29-31 October 2018.
Immuneed AB, a Swedish biotech service company, today announced that Charlotte Leife has been appointed as the company’s new Chief Executive Officer (CEO). The recruitment is a result of Immuneed’s rigorous growth and an important step in the company’s evolution into a global service provider. Immuneed will henceforth exclusively focus on immuno-service and promotion of its unique human whole-blood loop assay.
The Norwegian biotech company Ultimovacs AS took over the immunotherapy technology business of the Swedish company Immuneed AB last month. The complementary technologies of the two companies provide a unique platform for development of novel vaccine solutions for treatment and possibly prevention of cancer.